TheAnswerPage

JANUARY 9, 2022

Has CBDV been evaluated as an anti-seizure medication in clinical trials? Yes, GW Pharmaceuticals (the makers of Epidiolex) had trialed CBDV in adult epilepsy, but the study did not meet its primary endpoint of seizure reduction. That trial did not continue.

Clinical Trials 59

Clinical Trials Epilepsy Pharmaceutical Treatment 59

TheAnswerPage

MAY 25, 2022

The results of recent clinical trials indicate that Cannabidiol (CBD) reduces seizures among patients with refractory epilepsies of various etiologies. Most of these clinical studies report efficacy over short time periods (.

Clinical Trials 52

Clinical Trials Epilepsy Treatment CBD 52

Cannabis Law Report

MAY 31, 2022

The first path, that of traditional medicine, currently offers patients limited options. The only psychedelic drug that is approved (outside of clinical trials) for psychiatric use—as opposed to anesthesia—through the traditional medical system is Ketamine. 2022 Active FDA Clinical Trials and State-Regulated Systems.

Clinical Trials 52

Clinical Trials Legalization Therapy Decriminalization 52

Cannabis Law Report

MAY 19, 2022

This is Numinus’ first psilocybin-assisted therapy treatment outside of ongoing clinical trials, and among the first to use of this regulatory mechanism through Health Canada’s Special Access Program (“SAP”), which was amended January 5 th , 2022 to include access to psychedelic compounds on a case-by-case basis.

Therapy 52

Therapy Treatment Clinical Trials Access 52

Cannabis Law Report

FEBRUARY 24, 2022

Subsection 56(1) of the CDSA will exempt medical providers from enforcement of the CDSA when providing psilocybin and MDMA treatment to patients suffering serious or terminal health conditions. 01.015 of the FDR before providing the new drug to a patient. Timeline of Medicinal Legalization in Canada. Pursuant to subsection C.08.010(1)

Therapy 52

Therapy Access Clinical Trials Treatment 52

Cannabis Law Report

AUGUST 17, 2021

reduction in 28-day seizure frequency relative to baseline in tuberous sclerosis complex (TSC) patients (n=23). Secondary endpoint of 50% responder rate at 30.4%, consistent with the Marigold Phase 3 CDKL5 deficiency disorder trial results. reduction was observed in focal seizures (n=19), the most common seizure type in TSC patients.

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

Cannabis Law Report

AUGUST 10, 2022

9, 2022 /CNW/ – MediPharm Labs Corp. The lead investigators are Jacobo Mintzer , MD, MBA, Brigid Reynolds , ANP-BC, and the Alzheimer’s Clinical Trial Consortium (ACTC).The Dementia and related indications are hard to treat for patients and caregivers especially at the end-of-life stage. BARRIE, ON , Aug.

Clinical Trials 52

Clinical Trials Medicine Pharmaceutical THC 52

Veriheal

FEBRUARY 9, 2023

A fascinating new clinical trial demonstrates how this psychedelic compound could make people significantly more comfortable while undergoing MRIs or similar procedures. Although many rely on imaging scans to diagnose illnesses and get treatment of various kinds, getting into the enclosed chamber can be stressful. What Is an MRI?

Clinical Trials 98

Clinical Trials Research and Development Data Collective 98

Veriheal

MARCH 20, 2023

Both Colorado and Oregon allow patients to take psilocybin under the supervision of regulated and licensed “healing centers.” Smith cited results from clinical trials showing that MDMA holds promise in the treatment of PTSD. Utah In March 2022, Gov. Colorado has a wider range of psilocybin use. Missouri Rep.

Clinical Trials 98

Clinical Trials Therapy Decriminalization Treatment 98

Cannabis Law Report

AUGUST 13, 2021

Clinically, there are published reports of the potential benefits of Salvia divinorum in the treatment of TRD. Karl Hanes reported on 7 patients with TRD who described relief from depressive symptoms with continued oral consumption of salvia leaves three times a week.

Conditions 105

Conditions Research and Development Clinical Trials Treatment 105

Cannabis Law Report

APRIL 21, 2022

The availability of larger quantities of cGMP-compliant MDMA will facilitate ongoing clinical trials and provide for future therapeutic use following anticipated regulatory approvals. Publication of this process establishes “prior art,” contributing to MAPS’ patient access strategy by making intellectual property public .

Clinical Trials 52

Clinical Trials Research and Development Therapy Media 52

Cannabis Law Report

JUNE 17, 2021

Jazz said it expects to generate 65% of 2022 revenues from products that have been launched or acquired since 2019. As part of our continued R&D efforts we also look forward to advancing our PTSD and essential tremor programs, the nabiximols clinical trial program to support a U.S. net leverage by the end of 2022.

Pharmaceutical 108

Pharmaceutical Clinical Trials Therapy Programs 108

Cannabis Law Report

AUGUST 14, 2021

After acquiring the patented Gelpell technology through its acquisition of Satipharm in March, Cann is now looking to resume an internal development program with the aim of securing TGA approval for a Schedule 3 CBD product by the end of 2022. Shares in Cann Group were up 3.33 per cent to $0.31 while Emyria was up 7.89 per cent to $0.20

CBD 105

CBD Clinical Trials Programs Food 105

Cannabis Law Report

APRIL 2, 2022

Bienstar Plans To Build LATAM’s First Network of Integrative Mental Health Clinics. TORONTO, ON / ACCESSWIRE / March 31, 2022 / Novamind Inc. Upon signing a definitive agreement, Bienstar will have access to a broad patient base in Brazil-the largest market in Latin America with 215 million people.

Clinical Trials 52

Clinical Trials Research and Development Medicine Therapy 52

Cannabis Law Report

DECEMBER 9, 2021

(the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPD) a clinical stage pharmaceutical development company is pleased to announce that it has completed the manufacturing of its clinical grade supply (“cGMP”) of AP-188 (“ N , N -Dimethyltryptamine or DMT”) at Canadian manufacturer Dalton Pharma Services.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

FEBRUARY 9, 2022

09, 2022 (GLOBE NEWSWIRE) — Core One Labs Inc. (CSE: The application includes claims that Vocan’s technology will enable the production of cGMP API grade psilocybin, which can be used by pharmaceutical companies, API manufacturers and organizations conducting clinical trials and, where permitted by law, consumers, and patients.

Research and Development 52

Research and Development Clinical Trials Treatment Patients 52

Cannabis Law Report

JANUARY 24, 2022

Accomplished leader to oversee Goldfinch Bio’s clinical function to advance precision medicines for people living with kidney disease. Company is on track to announce interim data in mid-2022 from its Phase 2 clinical trial for lead kidney precision medicine product candidate GFB-887. CAMBRIDGE, Mass.–(BUSINESS

Clinical Trials 52

Clinical Trials Research and Development Data Medicine 52

Cannabis Law Report

SEPTEMBER 12, 2022

08, 2022 (GLOBE NEWSWIRE) — Optimi Health Corp. ( CSE: OPTI ) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), is pleased to announce that it has completed what it believes to be the largest legal natural psilocybin harvest in Canadian history. VANCOUVER, British Columbia, Sept. Penis Envy.

History 52

History Clinical Trials Legalization Research and Development 52

Cannabis Law Report

DECEMBER 26, 2021

. “With the filing of our provisional patent application, Entheon is building an IP foundation to better facilitate safe and precise use of psychedelics to deliver improved patient outcomes.” EBRX-101 on Track to Submit Regulatory Package for Human DMT Clinical Trial. ” In Vivo Toxicity Assays Completed.

Research and Development 52

Research and Development Clinical Trials Treatment Packaging 52

Cannabis Law Report

JANUARY 24, 2022

DUBLIN–(BUSINESS WIRE)–The “North America Legal Cannabis Market Size, Share & Trends Analysis Report by Sources (Marijuana, Hemp), by Derivatives (CBD, THC), by End Use (Medical, Recreational), and Segment Forecasts, 2022-2028” report has been added to ResearchAndMarkets.com’s offering. from 2022 to 2028.

Legalization 52

Legalization Supply Chain Chronic Pain Recreational 52

The Cannigma

MAY 13, 2022

There have been a number of preclinical and clinical trials studying cannabis’ effects on pain. 5 best desktop vaporizers for weed in 2022. One of the major reasons cannabis grew so popular with medical marijuana patients is its perceived ability to manage pain, particularly pain that other medications can’t help.

Terpenes 111

Terpenes Strains Chronic Pain Clinical Trials 111

Cannabis Law Report

JUNE 9, 2022

The bill would expand patients’ access to the necessary treatment for more than 50 conditions, including cancer and post-traumatic stress disorder (PTSD), neurological diseases, and chronic pain of neuropathic origin. Draft Law of Ukraine. ARV (revised). REFERENCE to the EU acquis. explanatory note. Comparative table. LAW OF UKRAINE.

Seed-To-Sale 52

Seed-To-Sale Legalization Cultivation Medicine 52

Cannabis Law Report

MAY 10, 2022

11 May 2022. This is despite a limited number of high-quality clinical trials investigating the drug’s efficacy for this condition. The authors note, however, that the data doesn’t include patient outcomes. This report from Vice on the back of new research released by the University of Sydney.

Medicine 52

Medicine Clinical Trials Sleep Data 52

Cannabis Law Report

MAY 12, 2022

Beckley Psytech to collaborate with Lophora on researching New Clinical Entities (NCE’s). May 11, 2022 02:00 AM Eastern Daylight Time. Lophora has previously secured grant funding from the BioInovation Institute (Novo Nordisk Foundation) and continues to characterise its lead candidates, aiming to initiate clinical trials in 2023.

Medicine 52

Medicine Research and Development Clinical Trials Treatment 52

Cannabis Law Report

MAY 29, 2022

To mitigate safety risks, FDA implemented a Risk Evaluation and Mitigation Strategy (REMS) with elements to assure safe use (ETASU) whereby patients self-administer the spray in their healthcare provider’s office under medical supervision. Clinical Trials and Human Subject Protections. 1, 2022), [link]. [14] 2] David E.

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

Cannabis Law Report

JANUARY 19, 2022

January 17, 2022. – January 17, 2022) – Psygen Industries Ltd. received a dealer’s licence issued by Health Canada on January 17, 2022 (the “ Dealer’s Licence “). received a dealer’s licence issued by Health Canada on January 17, 2022 (the “ Dealer’s Licence “).

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical Conditions 52

Cannabis Law Report

MAY 14, 2022

13 May 2022. By 2022, it is now difficult to find a high street or retail centre between John o’ Groats and Land’s End without CBD products for sale. In addition to the regulatory barriers to access, funding has long been cited as a problem, with limited patient access through the UK’s National Health Service.

Access 52

Access CBD Research and Development Medicine 52

Veriheal

MARCH 23, 2023

Aside from Japan legalizing medical marijuana and forging a legal pathway that enables patients to use drugs made from cannabis plants, the amended legal law also seeks to criminalize the use of marijuana. Data suggests that the market has inflated from JPY4 billion (USD$3 billion) in 2019 to JPY17 billion (USD$13 billion) in 2022.

Legalization 66

Legalization Marijuana Clinical Trials Seed-To-Sale 66

Cannabis Law Report

AUGUST 18, 2022

Psychedelics present a new potential path to relief for patients who continue to struggle with mental health conditions despite conventional therapies,” he added. BUFFALO, N.Y. , Aug. “The number of companies seeking to bring FDA-approved psychedelic medications to the market has exploded in the last few years.

Therapy 52

Therapy Research and Development Pharmaceutical Treatment 52

Cannabis Law Report

APRIL 21, 2022

Commercialization & Patient Access · Any City, Any State, California. It has been designated a Breakthrough Therapy by the FDA and the results of our pivotal Phase 3 clinical trial were published in Nature Medicine and profiled on the front page of The New York Times. About MAPS Public Benefit Corporation (MAPS PBC).

Advocacy 52

Advocacy Therapy Clinical Trials Environment 52

The Cannigma

JUNE 23, 2022

The study also found that CBGA interacts with numerous other important receptors in the body like GPR55, TRPV1 channels, as well as GABA receptors, supporting further consideration and research for use in epileptic patients. He noted, “The data in the study isn’t really ready for translation to the clinic.” Pain and inflammation.

Cannabinoids 113

Cannabinoids Research and Development Clinical Trials Extraction 113

Cannabis Law Report

NOVEMBER 16, 2021

Believed to be the only IND application ever cleared by the FDA for a Phase 2 trial of a patented drug for delaying aging. Phase 2 trial recruiting begins immediately; efficacy data expected by the end of the first quarter of 2022. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

SpeedWeed

SEPTEMBER 4, 2021

“DEA is proposing significant increases to the APQs of the schedule I substances psilocybin, psilocin, marihuana, and marihuana extract, which are directly related to increased interest by DEA registrants in the use of hallucinogenic controlled substances for research and clinical trial purposes,” the DEA writes. .

DEA 52

DEA Research and Development Clinical Trials Extraction 52

SpeedWeed

AUGUST 4, 2021

For the first time, he was a patient and not a criminal. They presented case studies about patients who have had incredible success from their cannabis treatments. I want to be a part of the change that sees patients become able to access quality cannabis medicines and to change lives. day/night, temperature, humidity).

Chronic Pain 52

Chronic Pain Research and Development Medicine Supply Chain 52

Cannabis Law Report

JANUARY 5, 2022

The patent will be issued on January 11, 2022. This patent issuance is rewarding and timely as we launch our Phase 2 trial of MYMD-1 as a therapy for sarcopenia, frailty, and aging, which is currently recruiting patients,” said Chris Chapman, M.D., Patent 11,219,620 B2, titled “Method of Treating Sarcopenia.” About MYMD-1.

Pharmaceutical 52

Pharmaceutical Clinical Trials Therapy Treatment 52

Cannabis Law Report

OCTOBER 29, 2021

(NYSE American: IGC) announces its financial results for the three months ended September 30, 2021, which is the second quarter of the Company’s 2022 fiscal year. The Company is preparing an INDA submission to the FDA for a Phase 2/3 trial for the use of IGC-AD1 to address symptoms associated with Alzheimer’s disease.

Clinical Trials 52

Clinical Trials Research and Development Data Business 52

Cannabis Law Report

DECEMBER 6, 2021

“We look forward to Jeff’s significant contributions heading into another year of continued growth and progress for Goldfinch Bio, including a planned interim data readout from TRACTION-2, the ongoing Phase 2 clinical trial of our lead precision kidney medicine candidate, in mid-2022.”.

Research and Development 52

Research and Development Supply Chain Clinical Trials Medicine 52